Company Profile

G1 Therapeutics Inc (AKA: G-Zero Therapeutics Inc)
Profile last edited on: 2/22/23      CAGE: 59AR1      UEI: L72RA25Z7LK3

Business Identifier: Myelosuppression treatments: next generation cancer therapies
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

79 TW Alexander Drive 4401 Research Commons Suite 105
Research Triangle Park, NC 27709
   (919) 213-9835
Location: Single
Congr. District: 04
County: Durham

Public Profile

Spun out of University of North Carolina, G1 Therapeutics, (NASDAQ:GTHX) -- fka G-Zero Therapeutics Inc - is structured around taking a small molecule-based approach to protecting bone marrow from damage due to chemotherapy or radiation. Bone marrow damage results in severe anemia, neutropenia, and thrombocytopenia. G1 Therapeutics' small molecules rapidly capture the cell cycle of hematopoeitic progenitor and stem cells in the bone marrow. This temporary capture -- termed pharmacological quiescence or Pharmacoquiescence (PQ) -- exploits the fact that when cells are detained in Go/G1 of the cell cycle, cells are more resistant to DNA damaging insults. One of the firm's technology applications is for radiation mitigants to treat individuals inadvertently exposed to lethal doses of radiation (radiation accident, atomic bomb, dirty bomb). Another addresses the problem of chemotherapy induced anemia, neutropenia, and thrombocytopenia. G1 Therapeutics is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 2 NIH $1,135,945
Project Title: Development of Gz38-1, a Novel Protectant of Chemotherapy-Induced Myelosuppressio
2013 1 NIH $159,836
Project Title: Development of Cdk4/6 Inhibitors as Novel Renal Protectants
2013 2 NIH $3,692,326
Project Title: Organismal Radioprotection Through Pharmacological Quiescence

Key People / Management

  Jack Bailey -- Chief Executive Officer

  Jay Copeland Strum -- President; Chief Scientific Officer; Chief Operations Officer

  Thomas Laundon -- Chief Financial Officer

  Rajesh Malik -- Chief Medical Officer

  Terry Murdock -- Chief Medical Officer

  Andrew Perry -- Chief Commercial Officer

  Patrick J Roberts -- Associate Director of Translational Medicine

  Christy L Shaffer -- Executive Chair

  Norman Sharpless -- Co-Founder

  Kwok-Kin Wong -- Co-Founder